Aren't you amazed about how fast the world has come together to find a collective solution for COVID-19? We have learned in the past months that we can compress the traditional vaccine paradigm, which is between 5 to 10 years to just 4 to 18 months.
The tremendous impact of the COVID crisis has significantly raised the global expectations and appreciation for innovation, digital, and excellence, which leads us to the question: what will the new normal be?
That's why there has never been a better time to connect, even virtually, in order to shape the transformation of the pharmaceutical industry with knowledge and expertise across the entire lifecycle.
Join us at the 2020 ISPE Biotechnology Virtual Conference on 7–8 October to hear from the experts as they discuss:
Your event experience includes access to two ATMP-focused workshops where you will discuss, debate, and identify potential deliverables.
Included in your conference registration are exclusive facilities tour of Produlab Pharma (PP), Catalent, and Takeda.
Designed to be highly interactive and hosted on a state-of-the-art digital platform, the 2020 ISPE Biotechnology Virtual Conference delivers the same high-quality content and premier engagement opportunities that you expect from this signature ISPE event.
I truly believe you and your team will find this event invaluable based on the opportunity for regulatory duty and comprehensive agenda addressing timely, industry-critical topics.
In addition, we are pleased to announce pricing for the 2020 ISPE Biotechnology Virtual Conference ranging from € 35 to € 495.
I look forward to seeing you there also for virtual networking!
The pharmaceutical industry stands at the cusp of a transformative era, where the integration of sustainability within the supply chain is not just a trend, but a necessity. The 2024 ISPE Annual Meeting &...
Although parenteral products make up only 1% of global pharmaceutical prescriptions by volume, at list price they now make up nearly half of global sales value, a percentage that has been increasing. Many of these are complex products produced in smaller batches for immunology or oncology, and a large majority are biologic therapies, which are generally poorly suited to oral formulations.
In 2020, CSL initiated a benchmarking activity with a small group of peer companies identified through ISPE to explore creation and maturation of asset management programs at each company. The initial sessions were a success, covering topics such as asset condition evaluations and asset management governance. CSL was keen to continue the conversations and gather more insights on certain...